Despite anecdotal reports to the contrary, a large observational study concludes that TNF inhibitors, compared with non-TNF biological or targeted synthetic DMARDs, do not cause higher rates of death or respiratory hospitalization in patients with RA-ILD.
In a powerful op-ed published by Fierce Healthcare, rheumatologists Amanda Myers, MD, and Rebecca Shepherd, MD, MBA—both volunteer advocates with the ACR—highlighted the critical role of the Centers for Medicare & Medicaid Services (CMS) in improving access to life-changing medications for patients with autoimmune and rheumatic diseases. Many patients with chronic conditions, such as rheumatoid…
The FDA will consider a supplemental new drug application for deucravacitinib for the treatment of adults with active psoriatic arthritis based on promising results from clinical trials.
The FDA has approved a new drug application for TNX-102 SL (Tonmya), a tablet with 2.8 mg of cyclobenzaprine HCl, after two clinical trials demonstrated the safety and effectiveness of the treatment in adults with fibromyalgia.
The roundtable included discussions on emerging issues in state advocacy, prior authorization reform, likely impacts of the Big Beautiful Bill and physician wellness.
Teresa J. Brady, PhD, MACR, Basia Belza, PhD, RN, FAAN, FGSA, Kimberly Kimpton, PT, MACR, & Marian T. Hannan, DSc, MPH, MACR |
Four past ARP presidents mark the organization’s 60th anniversary by examining its evolution alongside significant challenges & opportunities in the field.
Sjögren’s dry eye requires collaboration between rheumatologists and ophthalmologists for optimal patient management and treatment of this quality-of-life issue.